Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
gene therapy
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
biogen
boulder/denver blog main
boulder/denver top stories
crispr
deals
detroit blog main
detroit top stories
digital health
glaxosmithkline
indiana blog main
indiana top stories
medicare
national
nonalcoholic steatohepatitis
novartis
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
spinal muscular atrophy
startups
texas blog main
texas top stories
vc
wisconsin blog main
wisconsin top stories
zolgensma
What
remains
3
×
bio
new
roundup
allogene
approval
biogen’s
biopharmaceutical
cancer
companies
convo
crispr
crude
cutting
despite
diversity
drug
earlier
edge
effects
encoded
failures
gene
help
hot
illumina’s
immunotherapy
investors
ipo
juno
lasting
limited
limits
littered
long
medicine
million
nabs
nash
nearly
Language
Current search:
remains
×
biotech
×
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
